Skip to main content
Log in

Pentosanpolysulphate for interstitial cystitis

  • Review Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Interstitial Cystitis (IC) is a chronic disease of unknown etiology which primarily affects women aged 40–60 years. Many plausible theories for the development of IC have been postulated, and one current theory is that these patients have a quantitative and qualitative defect in the glycosaminoglycan (GAG) layer of the urothelium. Such a defect may allow toxic substances in the urine to gain access to the lamina propria and initiate a chronic inflammatory process. Pentosanpolysulphate (PPS) is a sulphated proteoglycan similar in structure to heparin sulphate, which is quantitatively the major GAG on cell surfaces. Exogenously administered PPS has been shown in several studies to decrease bladder pain and urinary frequency and to increase the voided volume. Further studies are required to evaluate the role of PPS in the management of IC patients, with particular emphasis on dosage, route of administration and combination with other compounds.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Nietze M. Lehrbuch de kystosskopie: Ihre lechnik und klinische bedeutung. Berlin: JE Bergman, 1907;410

    Google Scholar 

  2. Hunner GL. A rare type of bladder ulcer in women: report of cases.Boston Med Surg J 1915;172:660–664

    Google Scholar 

  3. Walsh A. Interstitial cystitis. In: Hanson JH, Gittes RF, Perlmutter AD, Stamey TA, Walsh PC, eds. Campbell’s urology, 4th edn. Philadelphia: WB Saunders, 1978;693–707

    Google Scholar 

  4. Oravisto KJ. Epidemiology of interstitial cystitis.Ann Chir Gynaecol 1975;64:75

    CAS  Google Scholar 

  5. Hanno P, Wein A, Pauly M, Held P. Epidemiology and serial cost of interstital cystitis.J Urol 1988;139–176

  6. De Juana CP, Everett JC. Interstitial cystitis, experience and review of recent literature.Urology 1977;10:325–329

    Article  Google Scholar 

  7. Koziol JC, Clark DC, Gittes RF, Tan EM. The natural history of interstitial cystitis: a survey of 374 patients.J Urol 1993;143:465–469

    Google Scholar 

  8. Messing EM, Stamey TA. Interstitial cystitis, early diagnosis, pathology and treatment.Urology 1978;12:381–392

    Article  PubMed  CAS  Google Scholar 

  9. Holm-Bentzen M, Jacobsen F, Nerstrom B et al. A prospective double-blind clinically controlled multicenter trial of Elmiron (sulphopentosan sodium) in the treatment of interstitial cystitis and related painful bladder diseases.J Urol 1987;137:503–507

    Google Scholar 

  10. Holm-Bentzen M, Lose G. Pathology and pathogenesis of interstitial cystitis.Urology 1987;29:8–13

    PubMed  CAS  Google Scholar 

  11. Messing EM. Interstitial cystitis and related syndromes. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED, eds. Campbell’s urology, 5th edn. Philadelphia: WB Saunders, 1992;982–1006

    Google Scholar 

  12. Dixon JS, Gosling JA. The anatomy of the bladder, urethra and pelvic floor. In: Mundy AR, Stephenson TP, Wein AJ, eds. Urodynamics. Principles, practice and application, 2nd edn. Edinburgh: Churchill Livingstone, 1994;3–14

    Google Scholar 

  13. Parsons CL, Boychuk D, Jones S, Hurst R, Callahan H. Bladder surface glycosaminoglycans: an epithelial permeability barrier.J Urol 1990;143:139–142

    PubMed  CAS  Google Scholar 

  14. Gregor HP. Anticoagulant activity of sulfonate polymers and copolymers. In: Gregor HP, ed. Polymer sciences and technology. New York: Plenum Press, 1975;5–56

    Google Scholar 

  15. Gregor HP. Fixed-charge ultrafiltration membranes. In: Selegny E. Charged gels and membranes. Amsterdam: D Reidel, 1976;235

    Google Scholar 

  16. Gryte CC, Gregor HP. Poly-(styrene sulfonic acid)-(vinyl-lidene fluoride) interpolymer ion-exchange membranes.Polym Sci 1976;14:1839

    CAS  Google Scholar 

  17. Parsons CL, Greenspan C, Moore SW, Mullholland SG. Role of surface mucin in primary antibacterial defence of bladder.Urology 1977;9:3:48–55

    Article  PubMed  CAS  Google Scholar 

  18. Dixon JS, Holm-Bentzen M, Gilpin CJ et al. Electron microscopic investigation of the bladder urothelium and glycocalyx in patients with interstitial cystitis.J Urol 1986;135:621–625

    PubMed  CAS  Google Scholar 

  19. Eldrup J, Thorup J, Nielson SL, Hald T, Hainau B. Permeability and ultrastructure of human bladder epithelium.Br J Urol 1983;55:488–492

    Article  PubMed  CAS  Google Scholar 

  20. Lepinard V, Saint-Andre JP, Rogan LM. La Cystite intestitielle.J d’Urol 1984;90:455–465

    CAS  Google Scholar 

  21. Fowler JE, Lau JLT, Ghosh L, Mounze A, Lynes WL. Interstitial cystitis is associated with intraurothelial Tamm-Horsfall protein.J Urol 1988;139:276

    Google Scholar 

  22. Holm-Bentzen M, Ammitzball T, Hald T. Glycosaminoglycans on the surface of the human urothelium: a preliminary report.Neurourol Urodyn 1986;5:519–523

    Article  CAS  Google Scholar 

  23. Sant GR, Ucci AA, Alroy J. Bladder glycosaminoglycans (GAGs) in interstitial cystitis.J Urol 1986;135:175

    Google Scholar 

  24. Comper WD, Laurent TC. Physiological function of connective tissue polysaccharides.Physiol Rev 1978;58:225–316

    Google Scholar 

  25. Jacques LB. Heparins — anionic polyelectrolyte drugs.Pharmacol Rev 1980;31:99–104

    Google Scholar 

  26. Weaver RG. Dougherty TF, Natolic CA. Recent concepts of interstitial cystitis.J Urol 1963;89:377–380

    PubMed  CAS  Google Scholar 

  27. Lose G, Jespersen J, Frandsen B, Hojensgaard JC, Astrup T. Subcutaneous heparin in the treatment of interstitial cystitis.Scand J Urol Nephrol 1985;19:27–29

    Article  PubMed  CAS  Google Scholar 

  28. Barrington JW, Fraylin L, Fish R, Shelley M, Stephenson TP. Elevated levels of basic fibroblast growth factor in the urine of clam enterocystoplasty patients.J Urol 1996;155:468–470

    Article  Google Scholar 

  29. Barrington JW, Fulford S, Fraylin L, Fish R, Shelley M, Stephenson TP. The use of pentosan polysulphate sodium to reduce urinary basic fibroblast growth factor in clam enterocystoplasty patients.Br J Urol 1996;78:54–56

    Google Scholar 

  30. Toozs-Hobson P, Gleeson C, Cardoza L. Interstitial cystitis — still an enigma after 80 years.Br J Obstet Gynaecol 1996;193:621–624

    Google Scholar 

  31. Parsons CL, Mulholland SG. Successful therapy of interstitial cystitis with pentosanpolysulfate sodium.J Urol 1987;138:513–516

    PubMed  CAS  Google Scholar 

  32. Mulholland SG, Hanno P, Parsons CL, Sant GR, Staskin DR. Pentosanpolysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study.Urology 1990;135:552–558

    Article  Google Scholar 

  33. Fritjofsson QA, Fall M, Juhlin R, Persson BE, Ruutu M. Treatment of ulcer and nonulcer interstitial cystitis with sodium pentosanpolysulfate: a multicenter trial.J Urol 1987;138:508–512

    PubMed  CAS  Google Scholar 

  34. Parsons CL, Benson G, Childs SJ, Hanno P, Sant GR, Webster G. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpoly-sulfate.J Urol 1993;150:845–848

    PubMed  CAS  Google Scholar 

  35. Perez-Marrero R, Emerson LE, Maharajh DO. Prolongation of response to DMSO by heparin maintenance.Urology 1993;41:64.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barrington, J.W., Stephenson, T.P. Pentosanpolysulphate for interstitial cystitis. Int Urogynecol J 8, 293–295 (1997). https://doi.org/10.1007/BF02765487

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02765487

Keywords

Navigation